Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2006 3
2007 2
2008 6
2009 5
2010 2
2011 2
2012 1
2013 2
2014 12
2015 8
2016 5
2017 5
2018 1
2019 3
2020 6
2021 8
2022 7
2023 7
2024 5
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for marzac c
Search for Manzac C instead (1 results)
Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution.
Rodriguez-Meira A, Norfo R, Wen S, Chédeville AL, Rahman H, O'Sullivan J, Wang G, Louka E, Kretzschmar WW, Paterson A, Brierley C, Martin JE, Demeule C, Bashton M, Sousos N, Moralli D, Subha Meem L, Carrelha J, Wu B, Hamblin A, Guermouche H, Pasquier F, Marzac C, Girodon F, Vainchenker W, Drummond M, Harrison C, Chapman JR, Plo I, Jacobsen SEW, Psaila B, Thongjuea S, Antony-Debré I, Mead AJ. Rodriguez-Meira A, et al. Among authors: marzac c. Nat Genet. 2023 Sep;55(9):1531-1541. doi: 10.1038/s41588-023-01480-1. Epub 2023 Sep 4. Nat Genet. 2023. PMID: 37666991 Free PMC article.
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, Dinner SN, Pigneux A, Montesinos P, Wang ES, Seiter KP, Wei AH, De Botton S, Arnan M, Donnellan W, Schwarer AP, Récher C, Jonas BA, Ferrell PB Jr, Marzac C, Kelly P, Sweeney J, Forsyth S, Guichard SM, Brevard J, Henrick P, Mohamed H, Cortes JE. Watts JM, et al. Among authors: marzac c. Lancet Haematol. 2023 Jan;10(1):e46-e58. doi: 10.1016/S2352-3026(22)00292-7. Epub 2022 Nov 10. Lancet Haematol. 2023. PMID: 36370742 Free PMC article. Clinical Trial.
Progressive chromatin rewiring by ETO2::GLIS2 revealed in a genome-edited human iPSC model of pediatric leukemia initiation.
Boudia F, Baille M, Babin L, Aid Z, Robert E, Rivière J, Galant K, Alonso-Pérez V, Anselmi L, Arkoun B, Abermil N, Marzac C, Bertuccio SN, de Prémesnil A, Lopez CK, Eeckhoutte A, Naimo A, Leite B, Catelain C, Metereau C, Gonin P, Gaspar N, Schwaller J, Bernard OA, Raslova H, Gaudry M, Marchais A, Lapillonne H, Petit A, Pflumio F, Arcangeli ML, Brunet E, Mercher T. Boudia F, et al. Among authors: marzac c. Blood. 2025 Apr 3;145(14):1510-1525. doi: 10.1182/blood.2024024505. Blood. 2025. PMID: 39656971
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients.
Willekens C, Bazinet A, Chraibi S, Bataller A, Decroocq J, Arani N, Carpentier B, Rausch C, Lebon D, Maiti A, Gauthier N, Short N, Bonnet S, Sasaki K, Khalife-Hachem S, Swaminathan M, Micol JB, Pasquier F, Marzac C, Roos-Weil D, Pascal L, Daver N, Kadia T, Bouscary D, Ravandi F, Pages A, Kantarjian H, De Botton S, DiNardo C. Willekens C, et al. Among authors: marzac c. Blood Cancer J. 2025 Apr 17;15(1):68. doi: 10.1038/s41408-025-01269-x. Blood Cancer J. 2025. PMID: 40246832 Free PMC article.
The ETO2 transcriptional cofactor maintains acute leukemia by driving a MYB/EP300-dependent stemness program.
Fagnan A, Aid Z, Baille M, Drakul A, Robert E, Lopez CK, Thirant C, Lecluse Y, Rivière J, Ignacimouttou C, Salmoiraghi S, Anguita E, Naimo A, Marzac C, Pflumio F, Malinge S, Wichmann C, Huang Y, Lobry C, Chaumeil J, Soler E, Bourquin JP, Nerlov C, Bernard OA, Schwaller J, Mercher T. Fagnan A, et al. Among authors: marzac c. Hemasphere. 2024 Jun 19;8(6):e90. doi: 10.1002/hem3.90. eCollection 2024 Jun. Hemasphere. 2024. PMID: 38903535 Free PMC article.
Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid Disorders.
Fandrei D, Pegliasco J, Pasquier F, Ibrahim N, Kfoury M, Berthon C, Heiblig M, Lebon D, Marçais A, Meunier M, Al Jijakli A, Lemasle E, Chantepie S, Pautas C, Dumas PY, Salanoubat C, Carp D, Loyaux R, Quivoron C, Pages A, Job B, Jelin R, Jules-Clement G, Antony-Debré I, Renneville A, Cotteret S, Itzykson R, Dombret H, Duployez N, Droin N, Leary A, Marzac C, Bernard E, Micol JB. Fandrei D, et al. Among authors: marzac c. Clin Cancer Res. 2025 Jun 3;31(11):2241-2253. doi: 10.1158/1078-0432.CCR-24-3683. Clin Cancer Res. 2025. PMID: 40162927
Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patients.
Vasseur D, Arbab A, Giudici F, Marzac C, Michiels S, Tagliamento M, Bayle A, Smolenschi C, Sakkal M, Aldea M, Sassi H, Dall'Olio FG, Pata-Merci N, Cotteret S, Fiévet A, Auger N, Friboulet L, Facchinetti F, Géraud A, Ponce S, Hollebecque A, Besse B, Micol JB, Italiano A, Lacroix L, Rouleau E. Vasseur D, et al. Among authors: marzac c. NPJ Precis Oncol. 2024 Feb 26;8(1):51. doi: 10.1038/s41698-024-00544-7. NPJ Precis Oncol. 2024. PMID: 38409229 Free PMC article.
Inferring the initiation and development of myeloproliferative neoplasms.
Hermange G, Rakotonirainy A, Bentriou M, Tisserand A, El-Khoury M, Girodon F, Marzac C, Vainchenker W, Plo I, Cournède PH. Hermange G, et al. Among authors: marzac c. Proc Natl Acad Sci U S A. 2022 Sep 13;119(37):e2120374119. doi: 10.1073/pnas.2120374119. Epub 2022 Sep 9. Proc Natl Acad Sci U S A. 2022. PMID: 36083966 Free PMC article.
82 results